Evidence map›Paper›PMID 27738390›Full record

ReviewMediators of inflammation2016

Exosomes and Exosomal miRNA in Respiratory Diseases.

Shamila D Alipoor, Esmaeil Mortaz, Johan Garssen, Masoud Movassaghi, Mehdi Mirsaeidi, Ian M Adcock

Registry-linked trialOpen access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Mediators of inflammation, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06002841 (Extracellular Vesicles From Mesenchymal Cells in the Treatment of Acute Respiratory Failure Associated With SARS-CoV-2 and Other Etiologies), which is not on this map. Cited by 79 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
79citing papers in PubMed, 2 pooled it
7.0field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06002841 phase1 / phase2unknown statusnot on this mapstarted 2024, after this paper: background citation

Extracellular Vesicles From Mesenchymal Cells in the Treatment of Acute Respiratory Failure Associated With SARS-CoV-2 and Other Etiologies: a Clinical Trial, Randomized, Double-blind.

TypeinterventionalSponsorD'Or Institute for Research and EducationRan2024 to 2025Enrolled15ConditionsSevere Acute Respiratory Syndrome (SARS), Acute Respiratory Distress Syndrome (ARDS), PneumoniaArmsintravenous treatment with EVs, intravenous treatment with placebo solution
3 · Its place in the literature

Who cites it

79 citing papers in PubMed, 2 syntheses or guidelines pooled it, 134 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Article
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review

19 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 5 institutions in 4 countries.

Shamila D AlipoorClinical Tuberculosis and Epidemiology Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran; Institute of Medical Biotechnology, Molecular Medicine Department, National Institute of Genetic Engineering and Biotechnology (NIGEB), Tehran, Iran.
Esmaeil MortazClinical Tuberculosis and Epidemiology Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran; Division of Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Faculty of Science, Utrecht University, Utrecht, Netherlands; Airways Disease Section, National Heart & Lung Institute, Imperial College London, London, UK.ORCID 0000-0002-7753-9624
Johan GarssenDivision of Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Faculty of Science, Utrecht University, Utrecht, Netherlands; Nutricia Research Centre for Specialized Nutrition, Utrecht, Netherlands.
Masoud MovassaghiDepartment of Pathology and Laboratory Medicine, University of California, Los Angeles (UCLA), Los Angeles, CA, USA.
Mehdi MirsaeidiDivision of Pulmonary, Critical Care, Sleep and Allergy, Department of Medicine, University of Miami Leonard M. Miller School of Medicine, Miami, FL, USA.ORCID 0000-0001-5298-8442
Ian M AdcockAirways Disease Section, National Heart & Lung Institute, Imperial College London, London, UK.ORCID 0000-0003-2101-8843
Utrecht University · NLImperial College London · GBMasih Daneshvari Hospital · IRUniversity of California, Los Angeles · USUniversity of Miami · US

Funding

Medical Research Council G1000758Medical Research Council G1001367Wellcome Trust
6 · The paper itself

Abstract

Exosomes are nanosized vesicles released from every cell in the body including those in the respiratory tract and lungs. They are found in most body fluids and contain a number of different biomolecules including proteins, lipids, and both mRNA and noncoding RNAs. Since they can release their contents, particularly miRNAs, to both neighboring and distal cells, they are considered important in cell-cell communication. Recent evidence has shown their possible importance in the pathogenesis of several pulmonary diseases. The differential expression of exosomes and of exosomal miRNAs in disease has driven their promise as biomarkers of disease enabling noninvasive clinical diagnosis in addition to their use as therapeutic tools. In this review, we summarize recent advances in this area as applicable to pulmonary diseases.

Indexed as

AnimalsExosomesHumansMicroRNAsRespiratory Tract DiseasesRNA, MessengerRNA, UntranslatedMicroRNAsRNA, MessengerRNA, Untranslated

Identifiers

PMID27738390
PMCPMC5055958
OpenAlexW2521810033

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.